Composite Outcomes in Clinical Trials: Uses and Problems;Resultados Compostos (Composite Outcomes) em Ensaios Clínicos: Usos e Problemas

Revista Portuguesa de Cardiologia

Volumn 22, Issue 10, 2003, Pages 1253-1263

  Vaz Carneiro, António ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Composite outcomes; Evidence based cardiology; Randomized controlled trials; Surrogate endpoints

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; OUTCOMES RESEARCH; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0344307422     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Carneiro AV. Aplicação ao doente individual dos resultados dos ensaios clínicos: regras práticas. Rev Port Cardiol 2003;22:259-68.
2. Soares I, Carneiro AV. Princípios de análise metodológica de ensaios terapêuticos. Part I: Validade dos resultados. Rev Port Cardiol 2002;21:457-69.
3. Guyatt GH, Rennie D, editors. User's Guides to the Medical Literature. A Manual for Evidence-Based Clinical Practice. Chicago: JAMA & Archives Journals AMA, 2001.
4. How to read a paper. The basics of evidence based medicine. London: BMJ Publishing Group, 2001.
5. Critical appraisal of epidemiological studies and clinical trials. Oxford: Oxford University Press, 1998.
6. Duley L, Farrell B, editors. Clinical trials. London: BMJ Books, 2002.
7. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
8. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: statistical principles for clinical trials. Stat Med 1999;18:1905-42.
9. Carneiro AV, Costa J. Marcadores de doença cardíaca em ensaios clínicos. Rev Port Cardiol 2002;21:1349-60.
10. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T, for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Int Med 2001;134:663-94.
11. Designing clinical research. Philadelphia: Lippincott Williams and Wilkins, 2001.
12. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
13. Lauer MS, Topol EJ. Clinical trials - multiple treatments, multiple endpoints, and multiple lessons. JAMA 2003;289:2575-7.
14. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ, for the IMPRESS investigators. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-20.
15. Dickstein K, Kjekshus J, and OPTIMAAL Steering Committee ftOSG. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
16. Gottlieb SS. Dead is dead - artificial definitions are no substitute. Lancet 1997;349:662-3.
17. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research. J Am Coll Cardiol 1999;34:618-20.
18. Shojania KG, Burton EC, McDonald KM, Goldman L. Changes in rates of autopsy-detected diagnostic errors over time. JAMA 2003;289:2849-56.
19. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
20. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials. Greater precision but with greater uncertainty? JAMA 2003;289:2554-9.
21. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
22. Sever PS, Dahlöf B, Poulter NR, Caulfield M, Collins R, Kjekshus J, Kristinsson A, McInnes GT, Mehlsen J, Nieminen MS, O'Brian E, Östergren J, for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
23. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
24. Shen Y, Thall PF. Parametric likelihoods for multiple non-fatal competing risks and death. Stat Med 1998;17:999-1015.
25. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
26. Pitt B, Poole-Wilson PA, Segal R, Neaton J, Sharma D, Thiyagarajan B, on behalf of the ELITE II Study Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial -the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.